A Phase 1b/2 trial of tazemetostat in combination with atezolizumab (TECENTRIQ) for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Atezolizumab (Primary) ; Tazemetostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 13 Mar 2018 Status changed from planning to recruiting, according to the Epizyme media release.
- 04 Aug 2017 According to an Epizyme media release, the company expects to begin enrolment in this study by the end of 2017.
- 04 Jul 2017 New trial record